Adaptimmune Therapeutics PLC (ADAPY): Capital Expenditures
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$886.0K
Year ended 2024-12-31
-53.1%
3-year compound annual growth
-11.1%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $886.0K | -81.1% | 2025-03-24, From 2024-01-01 |
| 2023-12-31 | $4.68M | -84.1% | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | $29.50M | +244.0% | 2025-03-24, From 2022-01-01 |
| 2021-12-31 | $8.57M | +266.3% | 2024-03-06, From 2021-01-01 |
| 2020-12-31 | $2.34M | +47.0% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $1.59M | -59.3% | 2022-03-14, From 2019-01-01 |
| 2018-12-31 | $3.91M | -84.1% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $24.64M | +114.2% | 2019-02-27, From 2017-01-01 |
| 2016-12-31 | $11.51M | n/a | 2019-02-27, From 2016-01-01 |
| No annual figure between 2015-06-30 and 2016-12-31. | |||
| 2015-06-30 | $5.08M | +271.9% | 2018-03-15, From 2014-07-01 |
| 2014-06-30 | $1.37M | n/a | 2017-03-13, From 2013-07-01 |